August 27, 2025 — Leads & Copy — Skye Bioscience, Inc. (Nasdaq: SKYE) will host a virtual Key Opinion Leader (KOL) event titled “Expert Panel on Peripheral CB1 Inhibition as a Mechanism for Weight Loss” on Thursday, September 4th at 8:00 AM ET.
The event will discuss expectations and details of upcoming topline results from the Phase 2a CBeyond™ trial of nimacimab, a first-in-class peripheral CB1 antibody for obesity.
The event will feature obesity key opinion leaders, covering success criteria in Skye’s Phase 2a study, the role of peripheral CB1 inhibition, newly generated preclinical data with nimacimab, and a Q&A session.
CEO Punit Dhillon said the KOL event will clarify expectations ahead of the Phase 2a topline data. The discussion will frame what constitutes success, discuss safety and tolerability, including gastrointestinal outcomes and neuropsychiatric considerations, and highlight how the data will be read against nimacimab’s target product profile. New preclinical insights will also be shared.
Featured speakers include Kevin Cannon, MD; Sean Wharton, MD, FRCPC, PharmD; and Marcus Goncalves, MD, PhD.
Advanced registration is required to participate in the webcast. The presentation and a replay will be available on the company’s website.
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®).
